IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL - PubMed
4 hours ago
- #ibrutinib
- #CLL
- #IGLV3-21R110
- IGLV3-21R110 is a mutation enabling autonomous B-cell receptor signaling in CLL, associated with poorer outcomes.
- In the CLL12 trial, IGLV3-21R110 was linked to shorter event-free survival across watch-and-wait, placebo, and ibrutinib groups.
- Multivariable analysis confirmed IGLV3-21R110 as an independent prognostic factor for reduced EFS (HR 3.18).
- IGLV3-21R110 reduced the clinical effectiveness of ibrutinib treatment, supported by in vitro assays showing impaired inhibition of signaling.